REVIEW

Microalbuminuria and cardiorenal risk: old and new evidence in different populations [version 1; peer review: 2 approved]

Diego Francisco Márquez¹, Gema Ruiz-Hurtado², Julian Segura², Luis Ruilope^{id}²⁻⁴

¹Unidad de Hipertensión Arterial-Servicio de Clínica Médica, Hospital San Bernardo, Salta, Argentina

²Instituto de Investigación Imas12 and Unidad de Hipertensión, Hospital 12 de Octubre, Madrid, Spain

³Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma, Madrid, Spain

⁴Escuela de Estudios Postdoctorales and Investigación, Universidad de Europa de Madrid, Madrid, Spain

V1 First published: 19 Sep 2019, 8(F1000 Faculty Rev):1659
<https://doi.org/10.12688/f1000research.17212.1>

Latest published: 19 Sep 2019, 8(F1000 Faculty Rev):1659
<https://doi.org/10.12688/f1000research.17212.1>

Abstract

Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.

Keywords

albuminuria, cardiovascular risk, chronic kidney disease

Open Peer Review

Approval Status

	1	2
version 1
19 Sep 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

- Peter Rossing**, Steno Diabetes Center
Copenhagen, Gentofte, Denmark
University of Copenhagen, Copenhagen,
Denmark
- Chi-yuan Hsu**, University of California, San
Francisco, San Francisco, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Diego Francisco Márquez (diegomarquez1@yahoo.com.ar)

Author roles: Márquez DF: Conceptualization, Writing – Review & Editing; Ruiz-Hurtado G: Conceptualization, Writing – Review & Editing; Segura J: Conceptualization, Writing – Review & Editing; Ruilope L: Conceptualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Márquez DF *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Márquez DF, Ruiz-Hurtado G, Segura J and Ruilope L. **Microalbuminuria and cardiorenal risk: old and new evidence in different populations [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1659 <https://doi.org/10.12688/f1000research.17212.1>

First published: 19 Sep 2019, 8(F1000 Faculty Rev):1659 <https://doi.org/10.12688/f1000research.17212.1>

Introduction

Mogensen was the first to describe the importance of microalbuminuria (MAU) not only as a renal risk factor but also as a powerful predictor of cardiovascular (CV) mortality in patients with type 2 diabetes mellitus (T2DM)¹. Since the description by Mogensen, MAU has received special attention as a prognostic marker for CV or renal risk or both, even in non-diabetic subjects². Mounting evidence indicates a continuous relationship between urinary albumin excretion (UAE) and cardiorenal risk, similar to the relationship between blood pressure (BP) and risk of CV events^{3–6}.

The presence of MAU implies dysfunction of the glomerular filtration barrier, which may result from hemodynamic-mediated mechanisms, functional or structural impairment of the glomerular barrier, or a combination of these⁷. In normal conditions, UAE can change in day-to-day measurements. Moreover, age, sex, body mass index, a high-protein meal, and vigorous exercise can promote a transient increase in albumin excretion. On the other hand, pathological conditions such as fever, congestive heart failure, urinary tract infection, and some drugs can also increase albumin excretion, so we have to consider all of these confounding factors when analyzing the urinary excretion of albumin⁸.

When MAU is present in pathological conditions, such as chronic kidney disease (CKD), diabetes, or hypertension (HTN), it represents the existence of renal target organ damage and is also a marker of CV morbidity and mortality and of progressive CKD. In this article, we will review the importance of MAU recognition and the management of this marker of cardiorenal risk.

Microalbuminuria diagnosis

There are different types of analysis to assess the presence of MAU. The urine dipstick, an insensitive marker for albuminuria, does not become positive until albumin excretion exceeds 300 to 500 mg/day. In normal conditions, UAE is less than 30 mg/day. When this value oscillates between 30 and 300 mg/day in a 24-hour urine collection or 30 to 300 mg/g of creatinine (urine albumin-to-creatinine ratio, or UACR) in a first morning sample, we used the term MAU, also known as “moderately increased albuminuria”. When albuminuria is more than 300 mg/day, it is considered macroalbuminuria^{8,9}. Although 24-hour urine collection is the gold standard for the detection of MAU, it has been suggested that screening can be carried out more simply. MAU can be tested from a first morning urine sample or at any time. In recent years, the albumin-to-creatinine ratio (ACR) from spot urine, preferably that first voided in the morning, may be considered equivalent to the values during a 24-hour urine collection^{7,10–12}.

Microalbuminuria in different populations

General “healthy” population

The prevalence of MAU in the general population varies from 2.2 to 11.8% in different studies^{13,14}. In the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study, a representation of the general population from Groningen (The

Netherlands) participated in a survey through a postal questionnaire and a vial to collect an early-morning urine sample to determine MAU. A total of 40,856 subjects (47.8%) responded. MAU was present in 7.2% of the subjects, and after exclusion of the diabetic and hypertensive subjects, MAU was still prevalent in 6.6% of the subjects¹³. Data from the US National Health and Nutrition Examination Survey (NHANES) showed an increase in prevalence of MAU (ACR of 30 to 300 mg/g) from 7.1 to 8.2% during the survey periods 1988 to 1994 and 1999 to 2004. The increase was attributed to older age of the population, prevalence of HTN and diabetes, and higher body mass index¹⁵. MAU in a “healthy population” is not a benign condition, and the evidence has shown an association between MAU and increased CV risk and all-cause mortality^{16–20}. In the above-mentioned PREVEND study¹³, UAE is a predictor of all-cause mortality in the general population^{18,19}. The Framingham Offspring Study of 1568 non-diabetic and non-hypertensive participants, which showed that low levels of UACR well below the current MAU threshold were associated with greater risk of CV disease (CVD), predicted the development of CVD (hazard ratio [HR] 1.36, 95% confidence interval [CI] 1 to 1.87) and of death (HR 1.55, 95% CI 1.10 to 2.20)⁵.

Moreover, the presence of MAU was associated with increased risk of incident HTN and also diabetes^{21–24}. There is strong evidence that the relationship between MAU and other CV risk factors, such as diabetes, HTN, left ventricular hypertrophy, hyperlipidemia, overweight, and metabolic syndrome, contributes to an increase in CV mortality^{6,25}.

Patients with diabetes

The classic definition of diabetic nephropathy is the presence of MAU that normally appears 5 to 10 years after the diagnosis of diabetes and that without adequate treatment progresses to end-stage renal disease (ESRD)²⁶. The cumulative incidences of MAU in patients with type 1 diabetes mellitus (T1DM) were 12.6% over 7.3 years, according to the European Diabetes (EURODIAB) Prospective Complications Study Group²⁷, and 33% in an 18-year follow-up study in Denmark²⁸. In patients with T2DM, the incidence of MAU showed an increase of 2.0% per year with a prevalence of 25% 10 years after diagnosis in the UK Prospective Diabetes Study (UKPDS)^{26,29}. Based on UAE values, diabetic nephropathy has been categorized into stages: MAU and macroalbuminuria. Cumulative evidence suggests that the risk for developing diabetic nephropathy and CVD starts when UAE values are still within the normoalbuminuric range^{30–32}. Although MAU has been considered a risk factor for macroalbuminuria, not all patients progress to this stage and some may regress to normoalbuminuria^{33,34}. Moreover, recent evidence reported that almost 25% of patients with T2DM and CKD with little or no proteinuria have biopsy-proven diabetic nephropathy and can progress to ESRD. The cause of this change in profile of diabetic nephropathy is unclear^{35,36}.

The natural history of diabetic nephropathy in patients with T1DM and T2DM is similar. However, the timing of diabetes diagnosis in T2DM is difficult to assess, and often target organ

damage is present when the diagnosis of T2DM is confirmed. T1DM allows a timeline picture of kidney disease progression starting with MAU and proceeds through stages of overt proteinuria, kidney function decline, and end-stage kidney disease^{37,38}. Nevertheless, this “classic” progression from MAU to macroalbuminuria is not seen in all patients. In fact, in patients with low levels of MAU (ACR of less than 100 mg/g) maintained for 2 to 3 years, it is possible to revert to normal UAE. Regression of MAU is facilitated by improved glucose, BP, and lipid control^{38,39}. On the other hand, epidemiological evidence unequivocally shows that albuminuria is a marker of subclinical renal damage and is associated with the progression of CKD as well as CVD in patients with diabetes^{29,32,39–41}. The relationship between albuminuria and decline of glomerular filtration rate (GFR) has been documented in many studies²⁶. In a 4-year study that included 194 Pima Indians with T2DM, the rate of GFR decreased by 3% in those with MAU at baseline ($P = 0.29$) and by 35% in those with macroalbuminuria ($P < 0.001$)³⁸. Ninomiya *et al.* showed that T2DM patients with both a UACR of 300 mg/g and an estimated GFR (eGFR) of less than 60 mL/minute per 1.73 m² had a 3.2-fold higher risk for CV events and a 22.2-fold higher risk for renal events compared with patients with neither of these risk factors⁴². These findings are similar in other ethnic patients with diabetes⁴³.

In an interesting study published recently, Minutolo *et al.*⁴⁴ compared the risk of all-cause mortality, fatal and non-fatal CV events, and ESRD between CKD patients with ($n = 693$) and without ($n = 1481$) diabetes. The authors stratified participants according to proteinuria level (<0.15 , 0.15 to 0.49 , 0.5 to 1 , and >1 g/day). During 4 years of follow-up, in the subgroup with UAE of less than 0.15 g/day, the risks of ESRD, CV events, and mortality were similar in diabetic and non-diabetic patients. Conversely, in patients with diabetes and CKD, the mortality risk was higher in patients with albuminuria of 0.15 to 0.49 g/day (HR 1.92, 95% CI 1.25 to 2.95), 0.5 to 1 g/day (1.99, 95% CI 1.26 to 3.15), and more than 1 g/day (1.98, 95% CI 1.28 to 3.06)⁴⁴.

Arterial hypertension

HTN is an established risk factor of CV and all-cause mortality^{45–47}. The prevalence of MAU in arterial HTN varies in different studies, ranging from 8 to 15%^{48–51}. However, in some studies, the prevalence was much higher⁵² and this wide difference may be due to differences in urine collection, cutoff level of normal albumin excretion, analytical methods, and the presence of anti-hypertensive medications.

Many studies have shown an association between MAU and BP circadian profile^{53–55}. Ambulatory BP monitoring has shown that nighttime BP levels are associated with MAU⁵⁶ and were a better predictor of major adverse CV events than office BP and 24-hour or daytime levels^{57,58}. In the general population, sustained HTN was associated with albuminuria. Moreover, the Hisayama study showed the association of white coat HTN and masked HTN with albuminuria in the general Japanese population⁵⁹. Similar findings were found for masked HTN^{60,61}.

In resistant hypertensive patients, Oliveras *et al.* found that true resistant HTN was associated with silent target organ damage, especially albuminuria⁶².

The European guidelines for HTN emphasize the importance of assessing the presence of organ damage for CV risk stratification, including the estimation of albuminuria⁶³. So it is very important that physicians look for the presence of MAU or subclinical renal involvement in patients with HTN to better assess CV risk stratification and develop strategies to control BP and reduced proteinuria⁶⁴.

Target organ damage

Different authors found an association between MAU as a marker of subclinical organ damage in non-diabetic hypertensive patients. The presence of MAU in patients with HTN was associated with a higher prevalence of left ventricular geometric patterns, especially concentric hypertrophy, assessed by either electrocardiography or echocardiography, compared with normoalbuminurics^{65–67}. The presence of MAU is also associated with several vascular structural and functional alterations^{68,69}, such as higher thickness of the intima and media of carotid artery compared with patients with normoalbuminuria⁷⁰, and predicts the development and progression of carotid atherosclerosis⁷¹.

MAU was also associated with retinal vascular damage in patients with HTN⁷². In patients with T1DM, MAU is a powerful predictor for the development of proliferative diabetic retinopathy and blindness⁷³. MAU was also identified as a marker of coronariopathy in diabetic and non-diabetic patients and in the general population and as a marker of cardiac dysfunction^{74–77}.

Chronic kidney disease

CKD is recognized as a major global public health problem^{3,78}. CKD affects 10 to 16% of the adult population and is an important risk factor for CVD events, particularly when albuminuria is present³. Available clinical practice guidelines have emphasized the use of current level of albuminuria as well as eGFR for CKD definition and staging^{79,80}. Different studies have shown the detrimental role that albuminuria plays in CKD progression and CV mortality in these populations⁸¹. Sumida *et al.* showed, in a cohort of 56,946 US veterans with eGFR of more than 60 mL/minute per 1.73 m², that relative changes in albuminuria over a 1-year interval were linearly associated with subsequent risk of kidney outcomes⁸². Similarly, in patients with diabetes, MAU and macroalbuminuria are associated with higher risks of CVD and of reduced eGFR compared with normoalbuminuria⁸³.

As the worsening of albuminuria leads to CKD progression, its reduction with specific treatment leads to improving kidney function, so that albuminuria could be considered a therapeutic target in clinical practice and a surrogate endpoint for ESRD^{84,85}. In the Stockholm CREAtinine Measurements (SCREAM) project, 31,732 individuals were studied with two or more ambulatory ACR tests to assess changes between ACR, ESRD, or death. Compared with stable ACR, a fourfold increase in ACR was associated with a 3.08-fold (95% CI 2.59

to 3.67) higher risk of ESRD and mortality, whereas a four-fold decrease in ACR was associated with a 0.34-fold (0.26 to 0.45) lower risk of ESRD⁸⁶. Different authors have documented mortality and morbidity associated with albuminuria changes^{87,88}.

In kidney transplant recipients, Weiner *et al.* recently reported that the presence of albuminuria (MAU and macroalbuminuria) in kidney transplant recipients was strongly associated with graft failure, CVD events, and death⁸⁹. This association is similar to that seen between albuminuria outcomes in the general population⁸⁹.

In recent decades, the BP target for hypertensive patients with CKD and proteinuria has been changing constantly. A few years ago, the recommended BP targets for the CKD population were less than 140/90 mm Hg and, if albuminuria was present, less than 130/80 mm Hg^{79,90-92}. The publication of the Systolic Blood Pressure Intervention Trial (SPRINT) in 2015 contributed to the consideration of a lower BP goal in non-diabetic CKD⁹³. SPRINT is a landmark study that randomly assigned 9361 persons without diabetes to a systolic BP (SBP) target of less than 120 mm Hg (intensive treatment) versus an SBP of less than 140 mm Hg (standard treatment). The authors concluded that targeting an SBP of less than 120 mm Hg, compared with less than 140 mm Hg, resulted in lower rates of fatal and non-fatal major CV events and death from any cause⁹³. In that trial, 28% of the study population had CKD (eGFR of 20 to less than 60 mL/minute per 1.73 m²), and in that group, intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcome and all-cause mortality as were seen in the full study cohort⁹³. Given that most patients with CKD die from CVD complications, SPRINT evidence supports a lower target of less than 130/80 mm Hg for all patients with CKD^{93,94}. However, observational studies of CKD cohorts indicate a higher risk of mortality at lower systolic pressures in elderly patients with CKD^{95,96}. In contrast, in the prespecified subgroup analysis of the elderly cohort in SPRINT, frail elderly patients did sustain benefit from the lower BP target, which supports a lower goal for all patients, including those with CKD⁹⁷. In contrast, data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study indicate that strict BP control (SBP of less than 120 mm Hg) did not improve renal outcomes in patients with T2DM⁹⁸. Since the publication of SPRINT, different guidelines have reviewed the BP target in the CKD population and support the BP target of less than 130/80 mm Hg for CKD patients independently of the presence of albuminuria^{63,99}.

Management of albuminuria: focus on pharmacotherapy

MAU is frequently present in asymptomatic patients. Recently, two meta-analyses assessed albuminuria as a surrogate endpoint for CKD progression in randomized controlled trials^{100,101}. Both articles found that the range in albuminuria was consistently associated with risk of end-stage kidney disease, lending support to the use of change in albuminuria as a surrogate endpoint for end-stage kidney disease^{100,101}. Given that MAU as

a marker of target organ damage is associated with CV mortality and CKD progression, it is important to treat these patients intensively.

Renin–angiotensin–aldosterone system blockade intervention trials

Reduction of albuminuria under anti-hypertensive treatment is associated with reduced risk of clinical CV events and at the same time renal protection^{102,103}. There is cumulative evidence of the efficacy of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) for the treatment of HTN in this population^{63,99,104,105}. A few trials that focus the intervention on MAU have been designed. In the Action in Diabetes and Vascular Disease (ADVANCE) trial, perindopril/indapamide was effective in preventing the onset of MAU, progression of MAU to macroalbuminuria, and even regression of albuminuria compared with placebo in patients with T2DM¹⁰⁶. Similarly, in the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial, olmesartan diminished the onset of MAU by 23% in T2DM¹⁰⁷. Dual renin–angiotensin–aldosterone system (RAAS) blockade between an ACEi plus an ARB should be avoided^{63,99}. This combination showed more cases of acute kidney injury and hyperkalemia without benefits^{108,109}. A similar result was found with the addition of the direct renin inhibitor aliskiren to an ACEi or ARB¹¹⁰. The combination of the standard therapy with an ACEi or an ARB with a mineralocorticoid receptor antagonist (MRA) is an interesting option for managing patients with albuminuria but has the inconvenience of frequent hyperkalemia in patients with CKD^{111,112}. In order to avoid the limitations of hyperkalemia of the traditional RAAS blockers in patients with CKD, new drugs have been developed¹¹³. The new non-steroidal MRA finerenone (BAY948862) has better MRA selectivity than spironolactone and also reduced albuminuria and end organ damage more effectively than eplerenone¹¹⁴. In the Mineralocorticoid Receptor Antagonist Tolerability Study (ARTS), finerenone reduced albuminuria from baseline levels and had a lower incidence of hyperkalemia when compared with spironolactone in patients with chronic heart failure¹¹⁵. Moreover, in the Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) study, different oral doses of finerenone in patients with T2DM reduced albuminuria¹¹⁶. The addition of the new potassium binder patiromer¹¹⁷ and the selective cation exchanger sodium zirconium cyclosilicate¹¹⁸ facilitated the use of traditional MRA in patients with CKD, reducing potassium levels¹¹⁹.

Glucose-lowering agents

In recent years, new anti-diabetic agents appeared not only showing benefits in glycemic control but also reducing CV mortality and improving kidney function. The SGLT2 inhibitor acts as a glycosuric agent. In the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME), empagliflozin or placebo was added to standard care in patients with T2DM and CVD¹²⁰. Empagliflozin reduced new or worsening nephropathy, doubling of serum creatinine (1.5% of the empagliflozin versus 2.6% placebo; $P < 0.001\%$),

and progression to macroalbuminuria (11.2% empagliflozin versus 16.2% placebo; $P < 0.001\%$)¹²¹. Similarly, in the CANagliflozin cardioVascular Assessment Study (CANVAS), canagliflozin or placebo was added to standard care in patients with T2DM with CVD or at high risk of CVD¹²². Active treatment with canagliflozin slowed the rate of eGFR decline and reduced UACR. Doubling of serum creatinine and new-onset macroalbuminuria were significantly reduced¹²².

Moreover, in the recently published Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy study (CREDENCE), patients with T2DM and CKD were randomly assigned to receive canagliflozin or placebo¹²³. The study was ended earlier because of recommendations from the safety committee. After 2.62 years, 4401 patients were randomly assigned. The event rates in the canagliflozin group and the placebo group were 43.2 and 61.2 per 1000 patient-years, respectively (HR 0.70, 95% CI 0.59 to 0.82; $P = 0.00001$), and the relative risk of the primary outcome was 30% lower in the canagliflozin group. The relative risk of end-stage kidney disease was lower by 32% (HR 0.68, 95% CI 0.54 to 0.86; $P = 0.002$), and the relative risks of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes were lower by 34% (HR 0.66, 95% CI 0.53 to 0.81; $P < 0.001$). The canagliflozin group had lower risks of hospitalization for heart failure (HR 0.61, 95% CI 0.47 to 0.80; $P < 0.001$) and CV death, myocardial infarction, or stroke (HR 0.80, 95% CI 0.67 to 0.95; $P = 0.01$)¹²³.

Two multicenter phase III trials with SGLT2 inhibitor looking for renal and CV endpoints are ongoing: the EMPA-Kidney with empagliflozin (ClinicalTrials.gov Identifier: NCT03594110) and the Dapa-CKD with canagliflozin (ClinicalTrials.gov Identifier: NCT03036150). Both studies aim to investigate the effect of SGLT2 inhibitors on kidney disease progression or CV death versus placebo.

GLP-1 agonists liraglutide¹²⁴ and semaglutide¹²⁵ have also shown a significant improvement in CV outcomes of patients with T2DM and were accompanied by a more significant

decrease in body weight and a less important drop in BP in the absence of natriuretic effects. This last point could explain the absence of effects on heart failure. Liraglutide also exhibited a renal protective capacity through a significant decrease in albuminuria¹²⁶.

Endothelin receptor antagonists

Endothelin receptor antagonists reduce albuminuria and BP but can also cause sodium retention. A previous trial with the non-selective endothelin receptor antagonist avosentan in patients with diabetes and CKD was stopped prematurely because of an increased incidence of heart failure¹²⁷. By contrast, short-term treatment with low doses of the more selective endothelin A receptor antagonist atrasentan reduced albuminuria without causing significant fluid retention^{128,129}. Recently, the Study of Diabetic Nephropathy with Atrasentan (SONAR) was published and showed a reduction in the risk of renal events with no significant differences for hospitalization for heart failure and also mortality compared with placebo¹³⁰.

Statins and fibrates

Drugs other than anti-hypertensives can influence MAU and renal function. Different meta-analyses showed reductions of MAU, proteinuria, and clinical deaths with statins^{131–133}. Fibrates showed also a reduction in albuminuria¹³⁴.

Conclusions

MAU is a specific integrated marker of CV risk and target organ damage in patients with HTN, CKD, and diabetes and its recognition is important for identifying patients at higher risk for CV mortality. The determination of albumin in 24-hour urine collection is the gold standard, but screening is usually made with the UACR (30 to 300 mg/g) in the first voiding urine. Using ACEi or ARB in these patients is recommended and recently more strategies for its management, such as the new anti-diabetic drugs or the novel MRA, have become available. At the moment, diagnosis of MAU is challenging because of the possibility of returning to normoalbuminuria with intensive treatment.

References

1. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med*. 1984; 310(6): 356–60. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
2. Mulè G, Castiglia A, Cusumano C, et al.: Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. *Adv Exp Med Biol*. 2017; 956: 279–306. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
3. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al.: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010; 375(9731): 2073–81. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Ruilope LM: The kidney as a sensor of cardiovascular risk in essential hypertension. *J Am Soc Nephrol*. 2002; 13 Suppl 3: S165–8. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Arnlöv J, Evans JC, Meigs JB, et al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation*. 2005; 112(7): 969–75. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Weir MR: Microalbuminuria and cardiovascular disease. *Clin J Am Soc Nephrol*. 2007; 2(3): 581–90. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Levey AS, Cattran D, Friedman A, et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *Am J Kidney Dis*. 2009; 54(2): 205–26. [PubMed Abstract](#) | [Publisher Full Text](#)

8. Mogensen CE, Vestbo E, Poulsen PL, *et al.*: Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. *Diabetes Care*. 1995; 18(4): 572–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Howey JE, Browning MC, Fraser CG: Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. *Clin Chem*. 1987; 33(11): 2034–8.
[PubMed Abstract](#)
10. Witte EC, Lambers Heerspink HJ, de Zeeuw D, *et al.*: First morning voids are more reliable than spot urine samples to assess microalbuminuria. *J Am Soc Nephrol*. 2009; 20(2): 436–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Miller WG, Bruns DE, Hortin GL, *et al.*: Current issues in measurement and reporting of urinary albumin excretion. *Clin Chem*. 2009; 55(1): 24–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. **F** Lambers Heerspink HJ, Gansevoort RT, Brenner BM, *et al.*: Comparison of different measures of urinary protein excretion for prediction of renal events. *J Am Soc Nephrol*. 2010; 21(8): 1355–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
13. Hillege HL, Janssen WM, Bak AA, *et al.*: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. *J Intern Med*. 2001; 249(6): 519–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Yuyun MF, Khaw KT, Luben R, *et al.*: Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study. *Eur J Cardiovasc Prev Rehabil*. 2004; 11(3): 207–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. **F** Coresh J, Selvin E, Stevens LA, *et al.*: Prevalence of chronic kidney disease in the United States. *JAMA*. 2007; 298(17): 2038–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
16. Romundstad S, Holmen J, Kvenild K, *et al.*: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. *Am J Kidney Dis*. 2003; 42(3): 466–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Yuyun MF, Khaw KT, Luben R, *et al.*: Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. *Int J Epidemiol*. 2004; 33(1): 189–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Hillege HL, Fidler V, Diercks GF, *et al.*: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation*. 2002; 106(14): 1777–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. **F** Chong J, Fotheringham J, Tomson C, *et al.*: Renal albumin excretion in healthy young adults and its association with mortality risk in the US population. *Nephrol Dial Transplant*. 2018; 375: 2073.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
20. Tanaka F, Komi R, Makita S, *et al.*: Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. *J Hypertens*. 2016; 34(3): 506–12; discussion 512.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Sung KC, Ryu S, Lee JY, *et al.*: Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality. *J Am Heart Assoc*. 2016; 5(9): pii: e003245.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Scheven L, van der Velde M, Lambers Heerspink HJ, *et al.*: Isolated microalbuminuria indicates a poor medical prognosis. *Nephrol Dial Transplant*. 2013; 28(7): 1794–801.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Takashima N, Ohkubo T, Miura K, *et al.*: Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. *J Hypertens*. 2012; 30(12): 2299–306.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hirayama A, Konta T, Hozawa A, *et al.*: Slight increase in urinary albumin excretion within the normal range predicts incident hypertension in a community-based Japanese population: the Takahata study. *Hypertens Res*. 2015; 38(1): 56–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. de Zeeuw D, Parving HH, Henning RH: Microalbuminuria as an early marker for cardiovascular disease. *J Am Soc Nephrol*. 2006; 17(8): 2100–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Marshall SM: Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. *Adv Chronic Kidney Dis*. 2014; 21(3): 267–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Chaturvedi N, Bandinelli S, Mangili R, *et al.*: Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. *Kidney Int*. 2001; 60(1): 219–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Hovind P, Tarnow L, Rossing P, *et al.*: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. *BMJ*. 2004; 328(7448): 1105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Adler AI, Stevens RJ, Manley SE, *et al.*: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int*. 2003; 63(1): 225–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. de Boer IH, Afkarian M, Rue TC, *et al.*: Renal outcomes in patients with type 1 diabetes and macroalbuminuria. *J Am Soc Nephrol*. 2014; 25(10): 2342–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. de Boer IH, Rue TC, Cleary PA, *et al.*: Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Arch Intern Med*. 2011; 171(5): 412–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. de Zeeuw D, Remuzzi G, Parving HH, *et al.*: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int*. 2004; 65(6): 2309–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Perkins BA, Ficociello LH, Silva KH, *et al.*: Regression of microalbuminuria in type 1 diabetes. *N Engl J Med*. 2003; 348(23): 2285–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? *Diabetes*. 2000; 49(9): 1399–408.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Dwyer JP, Lewis JB: Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. *Med Clin North Am*. 2013; 97(1): 53–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Koye DN, Magliano DJ, Reid CM, *et al.*: Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. *Am J Kidney Dis*. 2018; 72(5): 653–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Kussman MJ, Goldstein H, Gleason RE: The clinical course of diabetic nephropathy. *JAMA*. 1976; 236(16): 1861–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Nelson RG, Bennett PH, Beck GJ, *et al.*: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. *N Engl J Med*. 1996; 335(22): 1636–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** Oellgaard J, Gæde P, Rossing P, *et al.*: Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. *Kidney Int*. 2017; 91(4): 982–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
40. Umanath K, Lewis JB: Update on Diabetic Nephropathy: Core Curriculum 2018. *Am J Kidney Dis*. 2018; 71(6): 884–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Gerstein HC, Mann JF, Yi Q, *et al.*: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*. 2001; 286(4): 421–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Ninomiya T, Perkovic V, de Zeeuw BE, *et al.*: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol*. 2009; 20(8): 1813–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Afkarian M, Katz R, Bansal N, *et al.*: Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. *Clin J Am Soc Nephrol*. 2016; 11(8): 1384–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. **F** Minutolo R, Gabbai FB, Provenzano M, *et al.*: Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. *Nephrol Dial Transplant*. 2018; 33(11): 1942–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
45. Seo MH, Lee JY, Ryu S, *et al.*: The Effects of Urinary Albumin and Hypertension on All-Cause and Cardiovascular Disease Mortality in Korea. *Am J Hypertens*. 2017; 30(8): 799–807.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Ford ES: Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. *Circulation*. 2011; 123(16): 1737–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Fujiyoshi A, Ohkubo T, Miura K, *et al.*: Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. *Hypertens Res*. 2012; 35(9): 947–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Høegholm A, Bang LE, Kristensen KS, *et al.*: Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. *Hypertension*. 1994; 24(1): 101–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Palatini P, Graniero GR, Mormino P, *et al.*: Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). *Am J Hypertens*. 1996; 9(4 Pt 1): 334–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Pontremoli R, Sofia A, Ravera M, *et al.*: Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study.

- Microalbuminuria: A Genoa Investigation on Complications.** *Hypertension*. 1997; 30(5): 1135–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Jones CA, Francis ME, Eberhardt MS, *et al.*: Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. *Am J Kidney Dis*. 2002; 39(3): 445–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Böhm M, Thoenes M, Danchin N, *et al.*: Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the I-SEARCH global study. *J Hypertens*. 2007; 25(11): 2317–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Redon J, Liao Y, Lozano JV, *et al.*: Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. *J Hypertens*. 1994; 12(8): 947–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Bianchi S, Bigazzi R, Baldari G, *et al.*: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. *Am J Hypertens*. 1994; 7(1): 23–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Hansen KW, Mau Pedersen M, Marshall SM, *et al.*: Circadian variation of blood pressure in patients with diabetic nephropathy. *Diabetologia*. 1992; 35(11): 1074–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Ruiz-Hurtado G, Ruilope LM, de La Sierra A, *et al.*: Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. *Diabetes Care*. 2016; 39(10): 1729–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Fagard RH, Celis H, Thijs L, *et al.*: Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. *Hypertension*. 2008; 51(1): 55–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Dolan E, Stanton A, Thijs L, *et al.*: Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. *Hypertension*. 2005; 46(1): 156–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. **F** Hata J, Fukuhara M, Sakata S, *et al.*: White-coat and masked hypertension are associated with albuminuria in a general population: the Hisayama Study. *Hypertens Res*. 2017; 40(11): 937–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 60. Tomiyama M, Horio T, Yoshii M, *et al.*: Masked hypertension and target organ damage in treated hypertensive patients. *Am J Hypertens*. 2006; 19(9): 880–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Matsui Y, Eguchi K, Ishikawa J, *et al.*: Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. *Am J Hypertens*. 2007; 20(4): 385–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Oliveras A, Armario P, Hernández-del Rey R, *et al.*: Urinary albumin excretion is associated with true resistant hypertension. *J Hum Hypertens*. 2010; 24(1): 27–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Williams B, Mancia G, Spiering W, *et al.*: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*. 2018; 36(10): 1953–2041.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Leoncini G, Sacchi G, Ravera M, *et al.*: Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. *J Hum Hypertens*. 2002; 16(6): 399–404.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Pontremoli R, Ravera M, Bezante GP, *et al.*: Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. *J Hypertens*. 1999; 17(7): 993–1000.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Lieb W, Mayer B, Stritzke J, *et al.*: Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. *Nephrol Dial Transplant*. 2006; 21(10): 2780–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Tsioufis C, Stefanadis C, Toutouza M, *et al.*: Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. *J Hum Hypertens*. 2002; 16(4): 249–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Bigazzi R, Bianchi S, Nenci R, *et al.*: Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. *J Hum Hypertens*. 1995; 9(10): 827–33.
[PubMed Abstract](#)
 69. Rodondi N, Yerly P, Gabriel A, *et al.*: Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. *Nephrol Dial Transplant*. 2007; 22(4): 1107–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Geraci G, Mulé G, Costanza G, *et al.*: Relationship Between Carotid Atherosclerosis and Pulse Pressure with Renal Hemodynamics in Hypertensive Patients. *Am J Hypertens*. 2016; 29(4): 519–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Jorgensen L, Jenssen T, Johnsen SH, *et al.*: Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromsø Study. *Eur Heart J*. 2007; 28(3): 363–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Cerasola G, Cottone S, Mulé G, *et al.*: Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. *J Hypertens*. 1996; 14(7): 915–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Newman DJ, Mattock MB, Dawney AB, *et al.*: Systematic review on urine albumin testing for early detection of diabetic complications. *Health Technol Assess*. 2005; 9(30): iii–vi, xiii–163.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Jensen JS, Borch-Johnsen K, Feldt-Rasmussen B, *et al.*: Urinary albumin excretion and history of acute myocardial infarction in a cross-sectional population study of 2,613 individuals. *Eur J Cardiovasc Prev Rehabil*. 1997; 4(2): 121–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, *et al.*: Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation*. 2004; 110(1): 32–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. **F** Kumar Jha P, Ete T, Malviya A, *et al.*: Microalbuminuria: Correlation With Prevalence and Severity of Coronary Artery Disease in Non-Diabetics. *J Clin Med Res*. 2017; 9(10): 838–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 77. **F** Swoboda PP, McDiarmid AK, Erhayiem B, *et al.*: Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. *J Am Heart Assoc*. 2017; 6(7): pii: e005539.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 78. Navaneethan SD, Schold JD, Arrigain S, *et al.*: Cause-Specific Deaths in Non-Dialysis-Dependent CKD. *J Am Soc Nephrol*. 2015; 26(10): 2512–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int (Suppl.)*. 2013; 3(1): 1–150.
[Reference Source](#)
 80. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med*. 2013; 158(11): 825–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Ruggerenti P, Perna A, Mosconi L, *et al.*: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). *Kidney Int*. 1998; 53(5): 1209–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. **F** Sumida K, Molnar MZ, Potukuchi PK, *et al.*: Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. *Clin J Am Soc Nephrol*. 2017; 12(12): 1941–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 83. de Boer IH, Gao X, Cleary PA, *et al.*: Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. *Clin J Am Soc Nephrol*. 2016; 11(11): 1969–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Lambers Heerspink HJ, Gansevoort RT: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. *Clin J Am Soc Nephrol*. 2015; 10(6): 1079–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Heerspink HJ, Kröpelin TF, Hoekman J, *et al.*: Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. *J Am Soc Nephrol*. 2015; 26(8): 2055–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. **F** Carrero JJ, Grams ME, Sang Y, *et al.*: Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. *Kidney Int*. 2017; 91(1): 244–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 87. Schmieder RE, Mann JF, Schumacher H, *et al.*: Changes in albuminuria predict mortality and morbidity in patients with vascular disease. *J Am Soc Nephrol*. 2011; 22(7): 1353–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 88. Schmieder RE, Schutte R, Schumacher H, *et al.*: Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. *Diabetologia*. 2014; 57(10): 2019–29.
[PubMed Abstract](#) | [Publisher Full Text](#)
 89. **F** Weiner DE, Park M, Tighiouart H, *et al.*: Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney

- Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.** *Am J Kidney Dis.* 2019; 73(1): 51–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
90. Mancia G, Fagard R, Narkiewicz K, *et al.*: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J.* 2013; 34(28): 2159–219.
[PubMed Abstract](#) | [Publisher Full Text](#)
 91. James PA, Oparil S, Carter BL, *et al.*: 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA.* 2014; 311(5): 507–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Appel LJ, Wright JT Jr, Greene T, *et al.*: Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med.* 2010; 363(10): 918–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 93. SPRINT Research Group, Wright JT Jr, Williamson JD, *et al.*: A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med.* 2015; 373(22): 2103–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 94. Malhotra R, Nguyen HA, Benavente O, *et al.*: Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. *JAMA Intern Med.* 2017; 177(10): 1498–505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 95. Kovesdy CP, Alrifai A, Gosmanova EO, *et al.*: Age and Outcomes Associated with BP in Patients with Incident CKD. *Clin J Am Soc Nephrol.* 2016; 11(5): 821–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 96. Weiss JW, Peters D, Yang X, *et al.*: Systolic BP and Mortality in Older Adults with CKD. *Clin J Am Soc Nephrol.* 2015; 10(9): 1553–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 97. Williamson JD, Supiano MA, Applegate WB, *et al.*: Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. *JAMA.* 2016; 315(24): 2673–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 98. ACCORD Study Group, Cushman WC, Evans GW, *et al.*: Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med.* 2010; 362(17): 1575–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 99. Reboussin DM, Allen NB, Griswold ME, *et al.*: Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2018; 71(19): 2176–98.
[Publisher Full Text](#) | [F1000 Recommendation](#)
 100. Coresh J, Heerspink HJL, Sang Y, *et al.*: Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. *Lancet Diabetes Endocrinol.* 2019; 7(2): 115–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 101. Heerspink HJL, Greene T, Tighiouart H, *et al.*: Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol.* 2019; 7(2): 128–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 102. Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, *et al.*: Global cardiovascular protection in chronic kidney disease. *Nat Rev Cardiol.* 2016; 13(10): 603–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 103. Viazzi F, Muesan ML, Schillaci G, *et al.*: Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis. *J Hypertens.* 2016; 34(9): 1689–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
 104. Brenner BM, Cooper ME, de Zeeuw D, *et al.*: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001; 345(12): 861–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 105. Lewis EJ, Hunsicker LG, Clarke WR, *et al.*: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001; 345(12): 851–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 106. de Galan BE, Perkovic V, Ninomiya T, *et al.*: Lowering blood pressure reduces renal events in type 2 diabetes. *J Am Soc Nephrol.* 2009; 20(4): 883–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 107. Haller H, Ito S, Izzo JL Jr, *et al.*: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med.* 2011; 364(10): 907–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 108. ONTARGET Investigators, Yusuf S, Teo KK, *et al.*: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med.* 2008; 358(15): 1547–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 109. Fried LF, Emanuele N, Zhang JH, *et al.*: Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med.* 2013; 369(20): 1892–903.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 110. Parving HH, Brenner BM, McMurray JJ, *et al.*: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med.* 2012; 367(23): 2204–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 111. Mehdi UF, Adams-Huet B, Raskin P, *et al.*: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. *J Am Soc Nephrol.* 2009; 20(12): 2641–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 112. Márquez DF, Ruiz-Hurtado G, Ruilope LM, *et al.*: An update of the blockade of the renin angiotensin aldosterone system in clinical practice. *Expert Opin Pharmacother.* 2015; 16(15): 2283–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 113. Marquez DF, Ruiz-Hurtado G, Ruilope L: The impact of antihypertensives on kidney disease [version 1; peer review: 2 approved]. *F1000Res.* 2017; 6: 611.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 114. Kolkhof P, Delbeck M, Kretschmer A, *et al.*: Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. *J Cardiovasc Pharmacol.* 2014; 64(1): 69–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 115. Pitt B, Kober L, Ponikowski P, *et al.*: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. *Eur Heart J.* 2013; 34(31): 2453–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 116. Bakris GL, Agarwal R, Chan JC, *et al.*: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. *JAMA.* 2015; 314(9): 884–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 117. Weir MR, Bakris GL, Bushinsky DA, *et al.*: Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med.* 2015; 372(3): 211–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 118. Packham DK, Rasmussen HS, Lavin PT, *et al.*: Sodium zirconium cyclosilicate in hyperkalemia. *N Engl J Med.* 2015; 372(3): 222–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 119. Meaney CJ, Beccari MV, Yang Y, *et al.*: Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia. *Pharmacotherapy.* 2017; 37(4): 401–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 120. Zinman B, Wanner C, Lachin JM, *et al.*: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015; 373(22): 2117–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 121. Wanner C, Inzucchi SE, Lachin JM, *et al.*: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med.* 2016; 375(4): 323–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 122. Neal B, Perkovic V, Mahaffey KW, *et al.*: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med.* 2017; 377(7): 644–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 123. Perkovic V, Jardine MJ, Neal B, *et al.*: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med.* 2019; 380(24): 2295–306.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 124. Marso SP, Daniels GH, Brown-Frandsen K, *et al.*: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2016; 375(4): 311–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 125. Marso SP, Bain SC, Consoli A, *et al.*: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2016; 375(19): 1834–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 126. Mann JFE, Ørsted DD, Brown-Frandsen K, *et al.*: Liraglutide and Renal Outcomes in Type 2 Diabetes. *N Engl J Med.* 2017; 377(9): 839–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 127. Mann JFE, Green D, Jamerson K, *et al.*: Avasentan for overt diabetic nephropathy. *J Am Soc Nephrol.* 2010; 21(3): 527–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 128. Kohan DE, Pritchett Y, Molitch M, *et al.*: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. *J Am Soc Nephrol.* 2011; 22(4): 763–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 129. de Zeeuw D, Coll B, Andress D, *et al.*: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. *J Am*

Soc Nephrol. 2014; **25**(5): 1083–93.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

130. Heerspink HJL, Parving HH, Andress DL, *et al.*: **Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.** *Lancet.* 2019; **393**(10184): 1937–47.

[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

131. Douglas K, O'Malley PG, Jackson JL: **Meta-analysis: the effect of statins on albuminuria.** *Ann Intern Med.* 2006; **145**(2): 117–24.

[PubMed Abstract](#) | [Publisher Full Text](#)

132. Athyros VG, Katsiki N, Karagiannis A, *et al.*: **Statins can improve proteinuria**

and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? *Expert Opin Pharmacother.* 2015; **16**(10): 1449–61.

[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

133. Zhang Z, Wu P, Zhang J, *et al.*: **The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis.** *Pharmacol Res.* 2016; **105**: 74–83.

[PubMed Abstract](#) | [Publisher Full Text](#)

134. Jun M, Zhu B, Tonelli M, *et al.*: **Effects of fibrates in kidney disease: a systematic review and meta-analysis.** *J Am Coll Cardiol.* 2012; **60**(20): 2061–71.

[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Chi-yuan Hsu

Division of Nephrology, University of California, San Francisco, San Francisco, CA, USA

Competing Interests: No competing interests were disclosed.

2. Peter Rossing

¹ Steno Diabetes Center Copenhagen, Gentofte, Denmark

² University of Copenhagen, Copenhagen, Denmark

Competing Interests: Peter Rossing has received honoraria to his institution from services for AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, MSD, and Eli Lilly.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research